Navigation Links
NeurogesX to Present at Needham Life Sciences Conference
Date:6/3/2009

pathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. NeurogesX submitted a new drug application (NDA) for Qutenza to the U.S. Food and Drug Administration (FDA) in October 2008 for PHN, which was accepted for filing by the FDA in December 2008 and was given a Prescription Drug User Fee Act (PDUFA) date of August 16, 2009.

NeurogesX' second most advanced product candidate, NGX-1998, is a topically applied, liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions. NGX-1998 has completed three Phase 1 studies and NeurogesX is currently evaluating the timing of entering Phase 2 development.

NeurogesX' early stage product pipeline includes pre-clinical compounds, which are prodrugs of acetaminophen and various opioids. The company has evaluated these compounds in vitro and in vivo and is currently seeking development partners for these programs.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the expected timing and outcome of regulatory decisions and the label approval being sought or that may be obtained with respect to the NDA for Qutenza with the FDA; the size, scope and growth of potential markets for NeurogesX' product candidates; and the expected benefits of NeurogesX' product candidates and its plans with regard to seeking potential development partners for its early stage product pipeline. Such statements are based on management's current expectations, but actual results may diffe
'/>"/>

SOURCE NeurogesX, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. NeurogesX Receives European Commission Approval for Qutenza(TM)
2. NeurogesX Reports First Quarter 2009 Results
3. NeurogesX to Hold Conference Call to Discuss First Quarter 2009 Financial Results
4. NeurogesX Presents Two Posters at 61st Annual American Academy of Neurology Annual Meeting
5. NeurogesX to Hold Conference Call to Discuss Fourth Quarter and Year-End 2008 Financial Results and European Regulatory Update
6. NeurogesX Qutenza(TM) (NGX-4010) Receives Positive Committee Recommendation in European Union
7. NeurogesX to Present at 11th Annual BIO CEO & Investor Conference
8. NeurogesX to Present at Rodman & Renshaw 10th Annual Healthcare Conference
9. NeurogesX Reports Third Quarter 2008 Results
10. NeurogesX to Report Third Quarter 2008 Financial Results
11. NeurogesX Submits NDA for NGX-4010 Dermal Capsaicin Patch for Treatment of Postherpetic Neuralgia (PHN)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... , Aug. 31, 2015 Research and Markets ... "Middle East & Africa Biomedical Sensors Market - ... offering. The Middle East ... at $0.84 billion by 2018 at a CAGR of ... future will bring Biomedical sensors that are adaptable to ...
(Date:8/31/2015)... Aug. 31, 2015  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering and developing innovative therapies primarily in the ... the 30-day review period following the filing of ... indications with the U.S. Food and Drug Administration ... active. Logo -  http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
(Date:8/31/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 31, 2015 ... on the discovery and development of novel cancer immunotherapies, ... , M.D., Ph.D., as Chief Executive Officer and ... Drs. Wong and Ho join an experienced management team ... company: Jordan Fridman , Ph.D., Chief Scientific Officer; ...
(Date:8/31/2015)... IL (PRWEB) , ... August 31, 2015 , ... ... (PGIs), as a high priority in the drug development approval process. Thus, innovator ... , This year, Regis Technologies, Inc., a Chicago-based CMO, has been hosting multiple ...
Breaking Biology Technology:Middle East & Africa Biomedical Sensors Market Report 2015 - Growth, Trends & Forecasts to 2020 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 2RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 3RXi Pharmaceuticals Announces Advancements in its Ophthalmology Clinical Program with RXI-109 4FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 2FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 3FLX Bio Announces Senior Management Hires and Initiation of Phase 1 Trial of FLX925 4Regis Shares Expert Advice on Impurities in Drug Development 2Regis Shares Expert Advice on Impurities in Drug Development 3
... available in German . , They have been ... and now they are making rapid inroads in high performance ... cell phones and digital cameras. The automotive industry, for instance, ... increasingly using them in driver assistance systems from parking ...
... Scarguard Labs, LLC, a closely held company specializing in ... through the use of multi-technology drugs enhanced by a ... received approval from Health Canada to sell Scarguard to ... very pleased to gain approval for retail in our ...
... NEW YORK, Feb. 23, 2011 Stemline Therapeutics, Inc., ... that target cancer stem cells (CSCs), today announced that ... ("Pitt"), for the exclusive worldwide rights to a clinically ... tumor bulk and CSCs. Developed by Dr. Hideho Okada, ...
Cached Biology Technology:UV-transparent coating for image sensors 2Stemline Therapeutics Licenses Phase I/II Brain Cancer Vaccine - Shows Promise in Clinical Trial Conducted at University of Pittsburgh 2Stemline Therapeutics Licenses Phase I/II Brain Cancer Vaccine - Shows Promise in Clinical Trial Conducted at University of Pittsburgh 3
(Date:8/6/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ... today announced collaboration with Microsoft on biometric fingerprint ... leveraged Synaptics, deep expertise in human interface which ... Through stringent testing, Synaptics, advanced image sensing ... Precision TouchPad (PTP) specification empowering OEMs with Windows ...
(Date:8/5/2015)... , August 5, 2015 ... titled "Facial Recognition Market - Global Industry Analysis, Size, ... global market for facial recognition is forecast to reach ... by increased demand for surveillance systems by civil and ... number of crimes and terrorist activities across the globe ...
(Date:8/4/2015)... DUBLIN , Aug. 04, 2015 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/nvh7k2/digital_forensics ) has announced the addition ... Component (Hardware, Software, and Service), Sub-Segment (Computer ... Cloud Forensics), Tool Types, Service, Vertical and ... report to their offering. By ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... difficult to eliminate tumours effectively. Deciphering the strategies ... tumour cells and thus improve the clinical perspectives for ... and CNRS researchers have used two-photon microscopy to demonstrate, ... T lymphocytes infiltrate a solid tumour in order to ...
... discovered that the same ingredient used in dandruff shampoos ... head also can calm overexcited nerve cells inside your ... of the study can be found online in Nature ... result when nerves excessively or inappropriately “fire?in the brain. ...
... have developed two strategies to reactivate the p53 gene in ... The p53 protein is called the "guardian of the genome" ... , Inactivation of p53 can set the stage for the ... for the first time that inactivating the p53 gene is ...
Cached Biology News:How T lymphocytes attack 2How T lymphocytes attack 3Anti-dandruff compound may help fight epilepsy 2Turning a cellular sentinel into a cancer killer 2Turning a cellular sentinel into a cancer killer 3Turning a cellular sentinel into a cancer killer 4
...
... Normal;heading 1;heading 2;Many ... and experimental situations ... standard transfection and ... systems. ViraPower Lentiviral ...
LTBP-2 (7B10)...
... Rabbit polyclonal to Kv4.2 Immunogen ... corresponding to amino acids 23-43 of Rat ... with Rat.Expected to cross-react with Human (100% ... immunogen), Rabbit (100% identity with immunogen) and ...
Biology Products: